| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +6 more
PRINCE MERGER SUB II, LLC, a Delaware limited liability company; |
| 06 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On October 1, 2026, Bolt Biotherapeutics, Inc. (the “Company”) entered into the Second Amendment to Lease (the “Second Lease Amendment”) with HCP LS Redwood City LLC, as landlord (the “Landlord”). The Second Lease Amendment amends that c... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, Bolt Biotherapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in greater detail in... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 |
| 02 Oct 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Other Events
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study |
| 06 Jun 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Amendments to Articles/Bylaws; Change in Fiscal Year
Bolt Biotherapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: |
| 04 Jun 2025 |
8-K: Other Events
On May 27, 2025, the Board of Directors of Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), approved the filing with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Certifica... |
| 28 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 27, 2025, Bolt Biotherapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in greater detail in ... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
BDC-4182 Phase 1 dose-escalation study now open for enrollment |
| 16 Apr 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent. |
| 24 Mar 2025 |
8-K: Results of Operations and Financial Condition
BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 |
| 03 Jan 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on July 2, 2024, the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notified Bolt Biotherapeutics, Inc. (the “Company”) that, based on the previous 30 consecutive business days, its c... |
| 23 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 19, 2024, Dr. Mahendra Shah, Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of December 31,... |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers |
| 04 Sep 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 28, 2024, James Healy, M.D., Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of September 3, 2... |
Loading...